• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • Store
  • ION Awards
  • Podcasts
  • Full Measure
    • Full Measure Cover Stories
  • Donate
  • Bestseller "Slanted"

Sharyl Attkisson

Untouchable Subjects. Fearless, Nonpartisan Reporting.

  • US
  • World
  • Business
  • Health
    • Vaccine, Medical links
    • Omicron Lab Origin
    • Covid-19 Origins
    • Covid-19 Natural Immunity
    • Covid-19 Vaccine Concerns Summary
    • Covid-19 Vaccine: 80 Common Adverse Events
  • The Censored
  • Special Investigations
    • Attkisson v. DOJ
    • Media Mistakes, Biden Era
    • Media Mistakes on Trump
    • Other investigations
      • Benghazi
      • "Collusion v. Trump" TL
      • Election 2020
      • Fake News
      • Fast & Furious
      • Obamacare
      • Obama Surveillance TL
      • Other investigations
      • Ukraine 'Sabotage' of Trump TL

(READ) Review shows Merck's newly-approved pill for Covid-19, only 30% effective

Dated: December 1, 2021 by Sharyl Attkisson 1 Comment

      

Below is an excerpt from Medpage Today.

With the release of updated data, oral antiviral molnupiravir to treat high-risk COVID-19 showed only a 30% reduction in the risk of hospitalization and death, according to briefing documents from FDA staff.

The agent's sponsor, Merck, submitted data from the interim analysis of its phase III trial with the request for emergency use authorization (EUA).

This data, first published via press release in early October, showed a 50% risk reduction in all-cause hospitalization and death through day 29 (7.3% vs 14.1% for intervention and placebo groups, respectively).

The FDA's Antimicrobial Drugs Advisory Committee (AMDAC) met Tuesday (Nov 30) to vote on whether the drug's benefits outweigh its risks, and to discuss use of molnupiravir in pregnant women, as well as issues with viral mutations linked with the drug.

Note: The FDA advisory panel voted 13-10 to recommend the oral antiviral molnupiravir for emergency use authorization (EUA) for adults at high risk of progressing to severe COVID-19.

Read entire article here

  • Covid-19 Natural Immunity: The Definitive Summary
  • Covid-19 Vaccine: 80 of the Most Common Adverse Events
  • Covid-19 Vaccine Concerns Summary
  • Covid-19 Vaccine Analysis: Common Adverse Events
  • Covid-19 Origins: Separating Rumor from Fact (WATCH)
  • Report a Possible Vaccine Adverse Event

      
[the_ad id="17661"]

About Sharyl Attkisson

Emmy-Award Winning Investigative Journalist, New York Times Best Selling Author, Host of Sinclair's Full Measure

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Coming Soon

The Bad Shirts: High-Quality, Wearable Humor

The Sharyl Attkisson Store

Buy Great, Original Products & Support Independent Journalism

Subscribe

Get the Latest Stories Straight to Your Inbox

SUBSCRIBE TO SHARYL’S RUMBLE CHANNEL


Follow Sharyl Attkisson

  • Facebook
  • Instagram
  • RSS
  • Twitter
  • YouTube



Footer

Pages

  • Home
  • About
  • Podcast
  • Support
  • Contact

Sitemap

2ndary Pages

  • Full Measure Stations
  • Privacy Policy
  • Terms of Use
  • Newsletter
  • Returns & Refunds Policy

SPECIAL INVESTIGATIONS

  • Attkisson v. DOJ/FBI
  • Benghazi
  • Election 2020
  • Fake News
  • Fast & Furious
  • Obamacare

Copyright © 2023 ยท Log in